Correlation of Ki-67 Proliferative Antigen Expression and Tumor Response to Induction Chemotherapy Containing Cell Cycle-Specific Agents in Head and Neck Squamous Cell Carcinoma
Jonathan Alexander Chatzkel(University of Florida), Douglas R. Adkins(Washington University in St. Louis), James S. Lewis(Vanderbilt University Medical Center), Ryan S. Jackson(Washington University in St. Louis), Jason T. Rich(Washington University in St. Louis), Jingxia Liu(Washington University in St. Louis), Barry A. Siegel(Washington University in St. Louis), Brian Nussenbaum(Washington University in St. Louis), Mackenzie Daly(University of Colorado Colorado Springs), Randal C. Paniello, Wade L. Thorstad(Washington University in St. Louis), Tanya M. Wildes(University of Nebraska Medical Center), Farrokh Dehdashti(Washington University in St. Louis), Hiram A. Gay(Washington University in St. Louis), Jessica Ley(Washington University in St. Louis)
Cited by 11
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial
|The Lancet Oncology|2013|748
NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018
|Journal of the National Comprehensive Cancer Network|2018|632
NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022
|Journal of the National Comprehensive Cancer Network|2022|532